ArticleApplied microbiology and biotechnology2021
Cell culture-based production of defective interfering influenza A virus particles in perfusion mode using an alternating tangential flow filtration system.
Article in Applied microbiology and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Development of a scalable production bioprocess for HIV-1 virus-like particles coupling continuous VLP harvesting with end-to-end downstream processing.Scientific reports · 2026Article
- Process development for high-titer production of adenovirus devoid of replication-competent particles in suspension-adapted complementing A549 cell culture.BMC biotechnology · 2025Article
- Perfusion-Based Production of rAAV via an Intensified Transient Transfection Process.Biotechnology and bioengineering · 2025Article
- Perfusion Process Intensification for Lentivirus Production Using a Novel Scale-Down Model.Biotechnology and bioengineering · 2025Article
- Antivirotics based on defective interfering particles: emerging concepts and challenges.Frontiers in cellular and infection microbiology · 2025Review
- Innovations in cell culture-based influenza vaccine manufacturing - from static cultures to high cell density cultivations.Human vaccines & immunotherapeutics · 2024Review
- Production of antiviral "OP7 chimera" defective interfering particles free of infectious virus.Applied microbiology and biotechnology · 2024Article
- Digital Twin for Continuous Production of Virus-like Particles toward Autonomous Operation.ACS omega · 2024Article
- Optimization of Culture Media and Feeding Strategy for High Titer Production of an Adenoviral Vector in HEK 293 Fed-Batch Culture.Vaccines · 2024Article
- Mathematical model calibrated toiScience · 2024Article
- Production of recombinant vesicular stomatitis virus-based vectors by tangential flow depth filtration.Applied microbiology and biotechnology · 2024Article
- Intensified Influenza Virus Production in Suspension HEK293SF Cell Cultures Operated in Fed-Batch or Perfusion with Continuous Harvest.Vaccines · 2023Article
- Generation of "OP7 chimera" defective interfering influenza A particle preparations free of infectious virus that show antiviral efficacy in mice.Scientific reports · 2023Article
- Production of retroviral vectors in continuous high cell density culture.Applied microbiology and biotechnology · 2023Article
- Article
- Experimental studies from shake flasks to 3 L stirred tank bioreactor of nutrients and oxygen supply conditions to improve the growth of the avian cell line DuckCelt®-T17.Journal of biological engineering · 2023Article
- Novel suspension retroviral packaging cells generated by transposition using transposase encoding mRNA advance vector yields and enable production in bioreactors.Frontiers in bioengineering and biotechnology · 2023Article
- A novel bacteriocin against multiple foodborne pathogens fromCurrent research in food science · 2023Article
- Infecting kidney organoids with a cDNA reporter clone of SARS-CoV-2.STAR protocols · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Respiratory diseases including influenza A virus (IAV) infections represent a major threat to human health. While the development of a vaccine requires a lot of time, a fast countermeasure could be the use of defective interfering particles (DIPs) for antiviral therapy. IAV DIPs are usually characterized by a large internal deletion in one viral RNA segment. Consequentially, DIPs can only propagate in presence of infectious standard viruses (STVs), compensating the missing gene function. Here, they interfere with and suppress the STV replication and might act "universally" against many IAV subtypes. We recently reported a production system for purely clonal DIPs utilizing genetically modified cells. In the present study, we established an automated perfusion process for production of a DIP, called DI244, using an alternating tangential flow filtration (ATF) system for cell retention. Viable cell concentrations and DIP titers more than 10 times higher than for a previously reported batch cultivation were observed. Furthermore, we investigated a novel tubular cell retention device for its potential for continuous virus harvesting into the permeate. Very comparable performances to typically used hollow fiber membranes were found during the cell growth phase. During the virus replication phase, the tubular membrane, in contrast to the hollow fiber membrane, allowed 100% of the produced virus particles to pass through. To our knowledge, this is the first time a continuous virus harvest was shown for a membrane-based perfusion process. Overall, the process established offers interesting possibilities for advanced process integration strategies for next-generation virus particle and virus vector manufacturing.Key points• An automated perfusion process for production of IAV DIPs was established.• DIP titers of 7.40E + 9 plaque forming units per mL were reached.• A novel tubular cell retention device enabled continuous virus harvesting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.